文章基本信息

标题：Drugs under preclinical and clinical study for treatment of acute and chronic lymphoblastic leukemia
本地全文：下载
作者：Joe Antony Jacob ; Jumah Masoud Mohammad Salmani ; Baoan Chen 等
期刊名称：Patient Preference and Adherence
印刷版ISSN：1177-889X
电子版ISSN：1177-889X
出版年度：2016
卷号：10
页码：1115-1119
DOI：10.2147/PPA.S109477
出版社：Dove Medical Press Ltd
摘要：Targeted therapy has modernized the treatment of both chronic and acute lymphoblastic leukemia. The introduction of monoclonal antibodies and combinational drugs has increased the survival rate of patients. Preclinical studies with various agents have resulted in positive outputs with Phase III trial drugs and monoclonal antibodies entering clinical trials. Most of the monoclonal antibodies target the CD20 and CD22 receptors. This has led to the approval of a few of these drugs by the US Food and Drug Administration. This review focuses on the drugs under preclinical and clinical study in the ongoing efforts for treatment of acute and chronic lymphoblastic leukemia.
关键词：targeted therapy; monoclonal antibodies; preclinical studies; receptors; lymphoblastic leukemia